Literature DB >> 31255634

Epidemiology of adult meningitis during antiretroviral therapy scale-up in southern Africa: Results from the Botswana national meningitis survey.

Mark W Tenforde1, Margaret Mokomane2, Tshepo Leeme3, Nametso Tlhako3, Katlego Tsholo3, Chandapiwa Ramodimoosi4, Bonno Dube5, Kelebeletse O Mokobela5, Ephraim Tawanana6, Tony Chebani7, Tlhagiso Pilatwe7, William J Hurt3, Hannah K Mitchell3, Mooketsi Molefi8, Paul C Mullan9, Brandon L Guthrie10, Carey Farquhar11, Andrew P Steenhoff12, Madisa Mine2, Joseph N Jarvis13.   

Abstract

OBJECTIVES: Data on meningitis epidemiology in high HIV-prevalence African settings following antiretroviral therapy scale-up are lacking. We described epidemiology of adult meningitis in Botswana over a 16-year period.
METHODS: Laboratory records for adults undergoing lumbar puncture (LP) 2000-2015 were collected, with complete national data 2013-2014. Cerebrospinal fluid (CSF) findings and linked HIV-data were described, and national incidence figures estimated for 2013-2014. Temporal trends in meningitis were evaluated.
RESULTS: Of 21,560 adults evaluated, 41% (8759/21,560) had abnormal CSF findings with positive microbiological testing and/or pleocytosis; 43% (3755/8759) of these had no confirmed microbiological diagnosis. Of the 5004 microbiologically-confirmed meningitis cases, 89% (4432/5004) were cryptococcal (CM) and 8% (382/5004) pneumococcal (PM). Seventy-three percent (9525/13,033) of individuals undergoing LP with identifiers for HIV registry linkage had documented HIV-infection. Incidence of LP for meningitis evaluation in Botswana 2013-2014 was 142.6/100,000 person-years (95%CI:138.3-147.1); incidence of CM was 25.0/100,000 (95%CI:23.2-26.9), and incidence of PM was 2.7/100,000 (95%CI:2.4-3.1). In contrast to previously reported declines in CM incidence with ART roll-out, no significant temporal decline in pneumococcal or culture-negative meningitis was observed.
CONCLUSIONS: CM remained the predominant identified aetiology of meningitis despite ART scale-up. A high proportion of cases had abnormal CSF with negative microbiological evaluation.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cryptococcal meningitis; HIV; Pneumococcal meningitis; Sub-Saharan Africa; TB meningitis

Mesh:

Substances:

Year:  2019        PMID: 31255634      PMCID: PMC6679721          DOI: 10.1016/j.jinf.2019.06.013

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  30 in total

Review 1.  Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.

Authors:  Matthijs C Brouwer; Allan R Tunkel; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

2.  Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features.

Authors:  G E Thwaites; T T H Chau; K Stepniewska; N H Phu; L V Chuong; D X Sinh; N J White; C M Parry; J J Farrar
Journal:  Lancet       Date:  2002-10-26       Impact factor: 79.321

3.  23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial.

Authors:  N French; J Nakiyingi; L M Carpenter; E Lugada; C Watera; K Moi; M Moore; D Antvelink; D Mulder; E N Janoff; J Whitworth; C F Gilks
Journal:  Lancet       Date:  2000-06-17       Impact factor: 79.321

4.  Lumbar puncture in pediatric bacterial meningitis: defining the time interval for recovery of cerebrospinal fluid pathogens after parenteral antibiotic pretreatment.

Authors:  J T Kanegaye; P Soliemanzadeh; J S Bradley
Journal:  Pediatrics       Date:  2001-11       Impact factor: 7.124

5.  A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults.

Authors:  Neil French; Stephen B Gordon; Thandie Mwalukomo; Sarah A White; Gershom Mwafulirwa; Herbert Longwe; Martin Mwaiponya; Eduard E Zijlstra; Malcolm E Molyneux; Charles F Gilks
Journal:  N Engl J Med       Date:  2010-03-04       Impact factor: 91.245

6.  Presentation and outcome of tuberculous meningitis in a high HIV prevalence setting.

Authors:  Suzaan Marais; Dominique J Pepper; Charlotte Schutz; Robert J Wilkinson; Graeme Meintjes
Journal:  PLoS One       Date:  2011-05-19       Impact factor: 3.240

7.  Tuberculous meningitis in HIV-infected and non-infected patients: comparison of cerebrospinal fluid findings.

Authors:  D Cecchini; J Ambrosioni; C Brezzo; M Corti; A Rybko; M Perez; S Poggi; M Ambroggi
Journal:  Int J Tuberc Lung Dis       Date:  2009-02       Impact factor: 2.373

8.  Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa.

Authors:  Matthew Scarborough; Stephen B Gordon; Christopher J M Whitty; Neil French; Yasin Njalale; Alex Chitani; Timothy E A Peto; David G Lalloo; Eduard E Zijlstra
Journal:  N Engl J Med       Date:  2007-12-13       Impact factor: 91.245

9.  Tuberculous meningitis: a uniform case definition for use in clinical research.

Authors:  Suzaan Marais; Guy Thwaites; Johan F Schoeman; M Estée Török; Usha K Misra; Kameshwar Prasad; Peter R Donald; Robert J Wilkinson; Ben J Marais
Journal:  Lancet Infect Dis       Date:  2010-09-06       Impact factor: 25.071

10.  Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases.

Authors:  Joseph N Jarvis; Graeme Meintjes; Anthony Williams; Yolande Brown; Tom Crede; Thomas S Harrison
Journal:  BMC Infect Dis       Date:  2010-03-15       Impact factor: 3.090

View more
  3 in total

1.  Human Herpesvirus-6 Detection in Cerebrospinal Fluid on the BioFire FilmArray Meningitis/Encephalitis Panel in a High Human Immunodeficiency Virus-Prevalence African Setting.

Authors:  James Milburn; Kwana Lechiile; Keatlaretse Siamisang; Christopher G Williams; Leah Owen; Ezekiel Gwakuba; Tichaona Machiya; Tshepo Leeme; Hannah E Barton; Ronan Doyle; Mark W Tenforde; Madisa Mine; David M Goldfarb; Margaret Mokomane; Joseph N Jarvis
Journal:  Open Forum Infect Dis       Date:  2022-05-17       Impact factor: 4.423

2.  Reversal of CSF HIV-1 Escape during Treatment of HIV-Associated Cryptococcal Meningitis in Botswana.

Authors:  Nametso Kelentse; Sikhulile Moyo; Kesaobaka Molebatsi; Olorato Morerinyane; Shatho Bitsang; Ontlametse T Bareng; Kwana Lechiile; Tshepo B Leeme; David S Lawrence; Ishmael Kasvosve; Rosemary Musonda; Mosepele Mosepele; Thomas S Harrison; Joseph N Jarvis; Simani Gaseitsiwe
Journal:  Biomedicines       Date:  2022-06-13

3.  Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.

Authors:  Joseph N Jarvis; David S Lawrence; David B Meya; Enock Kagimu; John Kasibante; Edward Mpoza; Morris K Rutakingirwa; Kenneth Ssebambulidde; Lillian Tugume; Joshua Rhein; David R Boulware; Henry C Mwandumba; Melanie Moyo; Henry Mzinganjira; Cecilia Kanyama; Mina C Hosseinipour; Chimwemwe Chawinga; Graeme Meintjes; Charlotte Schutz; Kyla Comins; Achita Singh; Conrad Muzoora; Samuel Jjunju; Edwin Nuwagira; Mosepele Mosepele; Tshepo Leeme; Keatlaretse Siamisang; Chiratidzo E Ndhlovu; Admire Hlupeni; Constantine Mutata; Erik van Widenfelt; Tao Chen; Duolao Wang; William Hope; Timothée Boyer-Chammard; Angela Loyse; Síle F Molloy; Nabila Youssouf; Olivier Lortholary; David G Lalloo; Shabbar Jaffar; Thomas S Harrison
Journal:  N Engl J Med       Date:  2022-03-24       Impact factor: 176.079

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.